{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:16:26Z","timestamp":1783196186410,"version":"3.54.6"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81173133"],"award-info":[{"award-number":["81173133"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.jgar.2026.01.016","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T17:25:05Z","timestamp":1770657905000},"page":"64-72","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pharmacokinetic\/pharmacodynamic integration of linezolid alone and in combination with fosfomycin against methicillin-resistant Staphylococcus aureus in a neutropenic murine thigh infection model"],"prefix":"10.1016","volume":"47","author":[{"given":"Ziyan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhua","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangrui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sailan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaixing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2026.01.016_bib0001","article-title":"The continuing threat of methicillin-resistant Staphylococcus aureus","volume":"8","author":"Gajd\u00e1cs","year":"2019","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2026.01.016_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/ph14050420","article-title":"Mutation-based antibiotic resistance mechanism in methicillin-resistant Staphylococcus aureus clinical isolates","volume":"14","author":"Ali","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jgar.2026.01.016_bib0003","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2026.01.016_bib0004","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.01.016_bib0005","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2147\/DDDT.S164515","article-title":"Linezolid: a review of its properties, function, and use in critical care","volume":"12","author":"Hashemian","year":"2018","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jgar.2026.01.016_bib0006","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40360-022-00628-9","article-title":"Safety of linezolid in patients with decreased renal function and trough monitoring: a systematic review and meta-analysis","volume":"23","author":"Liu","year":"2022","journal-title":"BMC Pharmacol Toxicol"},{"key":"10.1016\/j.jgar.2026.01.016_bib0007","doi-asserted-by":"crossref","first-page":"927","DOI":"10.4065\/79.7.927","article-title":"Linezolid-associated peripheral neuropathy","volume":"79","author":"Rho","year":"2004","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jgar.2026.01.016_bib0008","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1001\/jama.2010.757","article-title":"Clinical outbreak of linezolid-resistant Staphylococcus aureus in an intensive care unit","volume":"303","author":"S\u00e1nchez Garc\u00eda","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jgar.2026.01.016_bib0009","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijantimicag.2018.09.013","article-title":"Resistance to fosfomycin: mechanisms, frequency and clinical consequences","volume":"53","author":"Falagas","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2026.01.016_bib0010","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1086\/511642","article-title":"Mutant selection window hypothesis updated","volume":"44","author":"Drlica","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.01.016_bib0011","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1186\/s12917-014-0297-1","article-title":"In vivo evaluation of mutant selection window of cefquinome against Escherichia coli in piglet tissue-cage model","volume":"10","author":"Zhang","year":"2014","journal-title":"BMC Vet Res"},{"key":"10.1016\/j.jgar.2026.01.016_bib0012","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13060833","article-title":"The role of PK\/PD analysis in the development and evaluation of antimicrobials","volume":"13","author":"Rodr\u00edguez-Gasc\u00f3n","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jgar.2026.01.016_bib0013","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1016\/j.bmc.2016.11.008","article-title":"Animal models in the pharmacokinetic\/pharmacodynamic evaluation of antimicrobial agents","volume":"24","author":"Zhao","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jgar.2026.01.016_bib0014","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2165\/00003088-200342150-00007","article-title":"Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme","volume":"42","author":"Rayner","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2026.01.016_bib0015","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ijid.2020.03.054","article-title":"Dosage regimen and toxicity risk assessment of linezolid in sepsis patients","volume":"96","author":"Dou","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2026.01.016_bib0016","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1128\/AAC.01194-06","article-title":"Pharmacokinetic\/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model","volume":"51","author":"Boak","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.01.016_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00605-19","article-title":"Reappraisal of Linezolid dosing in renal impairment to improve safety","volume":"63","author":"Crass","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.01.016_bib0018","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5249534","article-title":"Synergistic interaction of methanol extract from canarium odontophyllum miq. Leaf in combination with oxacillin against methicillin-resistant Staphylococcus aureus (MRSA) ATCC 33591","volume":"2016","author":"Basri","year":"2016","journal-title":"Int J Microbiol"},{"key":"10.1016\/j.jgar.2026.01.016_bib0019","article-title":"Synergistic combination of linezolid and fosfomycin closing each other\u2019s mutant selection window to prevent enterococcal resistance","volume":"11","author":"Jiang","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2026.01.016_bib0020","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/jac\/dky478","article-title":"Pharmacokinetics and pharmacodynamics of the novel monobactam LYS228 in a neutropenic murine thigh model of infection","volume":"74","author":"Growcott","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.01.016_bib0021","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1089\/mdr.2022.0119","article-title":"Investigations on in vivo pharmacokinetic\/pharmacodynamic determinants of fosfomycin in murine thigh and kidney infection models","volume":"29","author":"Chavan","year":"2023","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jgar.2026.01.016_bib0022","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ijantimicag.2013.12.001","article-title":"Activity of fosfomycin alone or combined with cefoxitin in vitro and in vivo in a murine model of urinary tract infection due to Escherichia coli harbouring CTX-M-15-type extended-spectrum \u03b2-lactamase","volume":"43","author":"Lefort","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2026.01.016_bib0023","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1080\/10408347.2019.1605876","article-title":"A critical review of HPLC-based analytical methods for quantification of Linezolid","volume":"50","author":"Fernandes","year":"2020","journal-title":"Crit Rev Anal Chem"},{"key":"10.1016\/j.jgar.2026.01.016_bib0024","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jchromb.2004.09.030","article-title":"Determination of linezolid in plasma and bronchoalveolar lavage by high-performance liquid chromatography with ultraviolet detection using a fully automated extraction method","volume":"813","author":"Toutain","year":"2004","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.jgar.2026.01.016_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.779885","article-title":"Pharmacodynamics of Linezolid plus Fosfomycin against vancomycin-resistant Enterococcus faecium in a hollow Fiber infection model","volume":"12","author":"Wang","year":"2021","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2026.01.016_bib0026","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","article-title":"Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial","volume":"42","author":"Stalker","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jgar.2026.01.016_bib0027","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1128\/CMR.00092-12","article-title":"Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents","volume":"26","author":"Gonzalez","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2026.01.016_bib0028","doi-asserted-by":"crossref","first-page":"5916","DOI":"10.1128\/AAC.01303-12","article-title":"Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model","volume":"56","author":"Lepak","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.01.016_bib0029","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00476-17","article-title":"In vivo pharmacokinetics and pharmacodynamics of ZTI-01 (Fosfomycin for injection) in the neutropenic murine thigh infection model against Escherichia coli, Klebsiella pneumoniae, and pseudomonas aeruginosa","volume":"61","author":"Lepak","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.01.016_bib0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-53714-0","article-title":"In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia","volume":"9","author":"Ku","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jgar.2026.01.016_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.1013939","article-title":"Effects of amikacin, polymyxin-B, and sulbactam combination on the pharmacodynamic indices of mutant selection against multi-drug resistant Acinetobacter baumannii","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2026.01.016_bib0032","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/ja.2014.5","article-title":"In vitro activity of fosfomycin in combination with linezolid against clinical isolates of methicillin-resistant Staphylococcus aureus","volume":"67","author":"Xu-Hong","year":"2014","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.jgar.2026.01.016_bib0033","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jmii.2018.12.007","article-title":"Synergistic effect of linezolid with fosfomycin against Staphylococcus aureus in vitro and in an experimental Galleria mellonella model","volume":"53","author":"Li","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jgar.2026.01.016_bib0034","first-page":"1544","article-title":"Prevalence of fosfomycin resistance and mutations in murA, glpT, and uhpT in methicillin-resistant Staphylococcus aureus strains isolated from blood and cerebrospinal fluid samples","volume":"6","author":"Fu","year":"2015","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2026.01.016_bib0035","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00775-17","article-title":"Pharmacokinetics, safety, and tolerability of single-dose intravenous (ZTI-01) and oral fosfomycin in healthy volunteers","volume":"61","author":"Wenzler","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.jgar.2026.01.016_bib0036","first-page":"ii17","article-title":"Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with gram-positive infections","volume":"51","author":"MacGowan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.01.016_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.967311","article-title":"Expert consensus statement on therapeutic drug monitoring and individualization of linezolid","volume":"10","author":"Lin","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.jgar.2026.01.016_bib0038","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02307-18","article-title":"Generating robust and informative nonclinical in vitro and in vivo bacterial infection model efficacy data to support translation to humans","volume":"63","author":"Bulitta","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.01.016_bib0039","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1128\/AAC.46.11.3484-3489.2002","article-title":"In vivo pharmacodynamics of a new oxazolidinone (linezolid)","volume":"46","author":"Andes","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.01.016_bib0040","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1093\/infdis\/jiaa016","article-title":"Pharmacodynamic correlates of linezolid activity and toxicity in murine models of tuberculosis","volume":"223","author":"Bigelow","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2026.01.016_bib0041","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00871-21","article-title":"Dose optimization of combined linezolid and fosfomycin against enterococcus by using an in vitro pharmacokinetic\/pharmacodynamic model","volume":"9","author":"Mao","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.jgar.2026.01.016_bib0042","article-title":"Fosfomycin: pharmacological, clinical and future perspectives","volume":"6","author":"Dijkmans","year":"2017","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2026.01.016_bib0043","article-title":"Synergy of linezolid with several antimicrobial agents against linezolid-methicillin-resistant staphylococcal strains","volume":"9","author":"Valderrama","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2026.01.016_bib0044","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1093\/jac\/dky129","article-title":"Increased activity of linezolid in combination with rifampicin in a murine pneumonia model due to MRSA","volume":"73","author":"Zhou","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.01.016_bib0045","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1093\/jac\/dkab095","article-title":"Anti-mutant efficacy of antibiotic combinations: in vitro model studies with linezolid and daptomycin","volume":"76","author":"Zinner","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.01.016_bib0046","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3389\/fmicb.2016.00874","article-title":"Relationship between cefquinome PK\/PD parameters and emergence of resistance of Staphylococcus aureus in rabbit tissue-cage infection model","volume":"7","author":"Xiong","year":"2016","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2026.01.016_bib0047","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-90709-2","article-title":"Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B-based combination therapy","volume":"11","author":"Fedrigo","year":"2021","journal-title":"Sci Rep"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526000160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526000160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:30:05Z","timestamp":1783193405000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716526000160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":47,"alternative-id":["S2213716526000160"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2026.01.016","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetic\/pharmacodynamic integration of linezolid alone and in combination with fosfomycin against methicillin-resistant Staphylococcus aureus in a neutropenic murine thigh infection model","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2026.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}